For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Ex-Drug Company Employees Accounts for 21 at PMDA
January 17, 2011
- Top-Leaders Stress Importance of Renovation in New Year's Addresses
January 17, 2011
- Mr Hasegawa to Lead Both KEIZAI DOYUKAI, Takeda
January 17, 2011
- BI Group to Inaugurate New Business Structure in Japan
January 17, 2011
- IBL to Develop Antibody Drugs Using Transgenic Silkworm
January 17, 2011
- Blopress Remains No. 1 for 7th Term in a Row: Domestic Drug Sales Ranking
January 17, 2011
- Mizuho Securities Lists Halaven, KW-0761 as Promising Anticancer Agents
January 17, 2011
- Pharma Industry Must Drive Nation's Economic Growth: Mr Matsuda
January 17, 2011
- Bayer, Regeneron Report Positive Results from 2 Studies on VEGF Trap-Eye
January 17, 2011
- Mr Matsutani Calls For Closer Cooperation with Makers to Settle Prices Quickly
January 17, 2011
- SymBio Starts PII Trial of Transdermal Antiemetic in Japan
January 17, 2011
- Morishita Jintan Merges Jintan Tech
January 17, 2011
- Prospects for Simultaneous Global Development: 3
January 17, 2011
- Addition of Noven Boosts Sales: Hisamitsu
January 17, 2011
- AnGes MG Granted Patent for NFκB Decoy Oligo
January 17, 2011
- Korosho to Accelerate Elimination of Drug-Lag: PS Okamoto
January 17, 2011
- JPA Opposed to Unification of Basic Dispensing Fees
January 17, 2011
- Korosho Considering PAL Amendment in 2012: Mr Masugi
January 17, 2011
- Korosho to Enhance Measures against ifestyle Diseases, Cancer, New-Types of Influenza
January 17, 2011
- Premium for New Drug Development Effective for Solving Drug-Lag Problem: MED Director
January 17, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…